Clinical Trial Update: Swedish Ibrance Registries Insights (SIRI)

View source ↗

Summary

Pfizer-sponsored registry study in Sweden evaluating Ibrance (palbociclib) for breast cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Malignant Neoplasm of Breast | Status: RECRUITING